

## Table of Contents

<b>Search terms and strategy</b> .....	<b>1</b>
<b>Prisma Flow charts</b> .....	<b>2</b>
<b>Data items</b> .....	<b>6</b>
<b>Forrest plots</b> .....	<b>6</b>

## Search terms and strategy

### Databases searched

The following databases were searched; EMBASE, PubMed, Cochrane and Clinicaltrials.gov. Previous systematic reviews were reviewed, and all included trials were cross-checked against our own search.

### Search terms

The search terms can be seen in table S1.

Table S1 Search terms used

Area	Keywords
Pediatric trial data – efficacy data	SARS / COVID /CORONA PAEDIATRIC / PEDIATRIC / CHILD* / ADOLESCENCE* / INFANT VACCIN* TRIAL EFFICACY / EFFECTIVE*
Pediatric safety data including clinical trials and post-marketing surveillance	SARS / COVID / CORONA PAEDIATRIC / PEDIATRIC / CHILD* / ADOLESCENCE* / INFANT TRIAL VACCIN* SAFE*

# Prisma Flow charts

Figure S1 Prisma flow chart - safety





Figure S2: Immunogenicity and Efficacy 1




## Data items

The following data were extracted where available for all studies which met inclusion criteria; first author, age of study subjects, study type, intervention measures (vaccine type, number of doses, etc), and trial location.

For studies included in the safety review the following information was also obtained: period of trial (as a rough analogue to predominant circulating SARS-CoV-2 strain), adverse events (including definitions, solicited, unsolicited, and serious). Given the heterogeneity of reported adverse effects, all of those listed in the primary paper and any supplemental material were extracted to allow comparison between studies. Data which was not presented with a numerical count or clear percentage (i.e., a bar chart with no data figures elsewhere in the text) was excluded.

## Forrest plots

Figure S3 Erythema dose 1 and 2






Figure S4 Swelling after dose 1 and 2





Figure S5 Fatigue after dose 1 and 2





Figure S6 Headache after dose 1 and 2




Figure S7 Nausea and vomiting after dose 1 and 2




Table S2 Safety databases and surveillance systems

Name of resource	Year	Vaccine given	Vaccine type	Location	Age of participants	Number vaccinated
COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021	2021	Pfizer	RNA	USA	12 to 17	approx 8.9 million
COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021	2021	Pfizer	RNA	USA	12 to 17	approx 8.9 million
Coronavirus vaccine - weekly summary of Yellow Card reporting	2022	Pfizer, AstraZeneca, Moderna	RNA, Viral vector	United Kingdom	<18	First dose: 4.2 million Second dose: 2.8 million
VigAccess	2022	All COVID-19 vaccines, unable to determine vaccine type by database	Mixed	Worldwide	Age data broken down into: 0-27 days, 28 days to 23 months, 2-11 years, 12-17 years, 18-44 years, 45-64 years, 65-74 years, >75 years	12 to 17 year olds: cumulative number of doses given in this age group: 5 to 11 year olds: Number of doses given in this age group: 5,020,764
Reported side effects following COVID-19 vaccination in Canada	2022	Pfizer	RNA	Canada	5 to 11, 12 to 17	Number of doses given in this age group: 5,020,764
COVID-19 Vaccines, Overview of National Reporting Experience Publication date: 17 February 2022 (Update #16)	2022	Pfizer	RNA	Ireland	5 to 11, 12 to 17	Total 875,000 doses in children between 5-17 years old
Adverse events following immunisation with COVID-19 vaccines: Safety Report #45 – 31 August 2022	2022	Pfizer	RNA	New Zealand	5 to 11, 12+	5-11: Dose 1: 267,314 Dose 2: 149,818 12 to 19 - data not available, instead data for 12+ presented by:
EudraVigilance	2022	Pfizer	RNA	EU / EEA	0-1 month, 2 months - 2 years, 3-11 years, 12-17 years	Not described in dashboard.
EudraVigilance	2022	Moderna	RNA	EU / EEA	0-1 month, 2 months - 2 years, 3-11 years, 12-17 years	Not described in dashboard.
EudraVigilance	2022	Astrazeneca	Viral vector	EU / EEA	0-1 month, 2 months - 2 years, 3-11 years, 12-17 years	Not described in dashboard.
EudraVigilance	2022	Janssen	Viral vector	EU / EEA	0-1 month, 2 months - 2 years, 3-11 years, 12-17 years	Not described in dashboard.
Moderna COVID-19 vaccine safety data - Adolescent participants	2022	Moderna	RNA	Australia	<20	Surveys completed: Moderna dose 1: 5,362 Moderna dose 2: 4847
Pfizer COVID-19 vaccine safety data - Child participants	2022	Pfizer	RNA	Australia	5 to 11	Surveys complete: Pfizer dose 1: 133,618 Pfizer dose 2: 82,340
Pfizer COVID-19 vaccine safety data - Adolescent participants	2022	Pfizer	RNA	Australia	<20	Surveys completed: Pfizer dose 1: 231,093 Pfizer dose 2: 172,002 Pfizer dose 3 / booster: 35,155
VAERS	2022	Pfizer	RNA	USA		Not described in dashboard.
VAERS	2022	Moderna	RNA	USA		Not described in dashboard.